Research & Development

At Swiss Rockets, our primary goal is to improve human health through innovative research and development of therapies and vaccines to treat and prevent severe diseases. Our interdisciplinary team of experts, including chemists, molecular biologists, virologists, immunologists, translational scientists, and clinicians, is dedicated to advancing treatments within oncology and infectiology. By discovering new medical treatments that are effective, safe, and affordable, we strive to improve and extend people's lives. Our cutting-edge research is pushing the boundaries of medical knowledge and making a meaningful impact in the world of healthcare.

Focused on advancing treatments within oncology, infectious diseases, and auto-immune disorders.


Pioneering Next-Gen Vaccines for a Healthier Future RocketVax AG, a Swiss biotech firm established in 2020, originated from a collaboration between Swiss Rockets AG, Gigabases Switzerland AG, and top researchers from Swiss and German renowned institutions. Together, we aim to revolutionize disease prevention through next-generation vaccine development. In partnership with leading research centers, RocketVax has created three innovative, live-attenuated SARS-CoV-2 vaccines using cutting-edge reverse genetic engineering technology: - RVX-sCPD9 – slow-replicating SARS-CoV-2 vaccine - RVX-OTS228 – normal-to-stop replicating SARS-CoV-2 vaccine - RVX-13 – replication-incompetent SARS-CoV-2 vaccine Administered nasally, these vaccines stimulate potent mucosal immunity, producing neutralizing antibodies and T-immune cells for comprehensive, enduring protection against the SARS-CoV-2 and its variants. Following clinical trial validation, these next-gen COVID-19 vaccines have the potential to dominate the seasonal vaccine market. The renowned institutions involved in the collaboration with RocketVax AG include: 1. University of Basel 2. University Hospital Basel 3. Swiss Tropical and Public Health Institute in Basel 4. University of Zurich 5. ETH Zurich 6. University of Bern 7. Swiss Federal Institute of Virology and Immunology 8. University of Geneva 9. University Hospital Geneva 10. Freie Universität Berlin 11. Friedrich Loeffler Institute, Federal Research Institute of Animal Health of Germany


Torqur AG is a Swiss biotech startup launched in 2021 with the aim to deliver precise, effective, and safe targeted therapy to cancer patients worldwide. This platform is designing and developing more active and safer next-generation PI3K/mTOR inhibitors. The lead candidate is the brain penetrable drug bimiralisib (PQR309), which showed promising efficacy signals in phase I and II clinical trials in various types of cancers. TORQUR has the vision to develop efficient and affordable targeted therapies with minimal toxicity, aiming to improve the quality of life for cancer patients.